#AskAbsci: How does Absci evaluates millions of drug candidate sequences and cell line architectures in parallel? | Absci #AskAbsci: How does Absci evaluates millions of drug candidate sequences and cell line architectures in parallel? | Absci

05.11.2022

#AskAbsci: How does Absci evaluates millions of drug candidate sequences and cell line architectures in parallel?

Imagine being able to evaluate millions of drug candidate sequences and cell line architectures in parallel. That’s exactly what Absci’s technology allows. Watch the short video about to learn how with our CTO Matthew Weinstock.

Question: How does Absci evaluate millions of drug candidate sequences and cell line architectures in parallel?

Answer: Our proprietary assays, the ACE assay and our HiPrBindTM assay, allow us to evaluate and sort the millions to billions of drug sequences and cell line variants we generate.

Using our high-throughput ACE assay which relies upon flow cytometry methods, we can quickly assess millions and even billions cells in populations and sort them into subset groups based on the characteristics we desire – this includes not only raw expression levels but we can also assess binding affinity for the target with this assay. With HiPrBindTM assay, using automated multiplexed plate-based methods, we grow micro-batches of hundreds or thousands of selected strains isolated from the ACE assay and perform quantitative characterization of protein function and titer. We also perform high- and mid-throughput biophysical characterization to collect additional data on relevant attributes that impact developability.